A Multicenter Study by the DENO Research Group on the Use of Denosumab in Giant-Cell Tumors of the Bone
Por:
Calva, CD, Angulo, M, González-Rojo, P, Peiró, A, Machado, P, Cebrián, JL, García-Maroto, R, Valcárcel, A, Puertas, P, Valero-Cifuentes, G, Pablos, O, Maireles, M, Fontalva, ML, Chaves, I, Orce, A, Coll-Mesa, L, Pérez, I, González, F, Sanz, MD, Gracia, I
Publicada:
7 may 2025
Resumen:
Background/Objectives: Despite the therapeutic potential of denosumab for the treatment of giant-cell tumors of the bone (GCTBs), there is a lack of standardization in treatment protocols. Methods: We present a multicenter, retrospective, descriptive study conducted across the seven hospitals in Spain affiliated with the DENO Research Group. Seventy-three patients diagnosed with GCTB and treated with denosumab were included and stratified according to treatment strategy-neoadjuvant (n = 38), adjuvant (n = 8), and single treatment (n = 27). Results: Patients in the neoadjuvant group received denosumab for a median of 6.1 months, with reintroduction after surgery in 25.8% of all cases. Among the neoadjuvant patients treated with curettage, recurrence was 35.5%, with no association with denosumab treatment duration (p = 0.274) nor with denosumab reintroduction after surgery (p = 0.405). In the adjuvant group, those who completed treatment received denosumab for 15.3 months, while those still undergoing therapy received it for a median of 12.8 months; only one case (12.5%) recurred. Recurrence rates in neoadjuvant and adjuvant treatment strategies were not different (p = 0.394). Patients treated only with denosumab and no longer on treatment had received it for 34.2 months, with 31.3% recurrence; those still on treatment had received it for 51.8 months, with 25.0% recurrence. Across all strategies, more than 85% of patients reported favorable clinical outcomes, and only 43.8% presented adverse events. No deaths occurred during this study. Conclusions: Although patients who experienced recurrence during neoadjuvant treatment had longer durations of denosumab administration, the difference was not statistically significant. Similarly, recurrence rates did not differ significantly, whether denosumab was reintroduced after surgery or not. Among the patients treated with curettage, recurrence rates were comparable between neoadjuvant and adjuvant strategies. Discontinuation of the single treatment did not necessarily result in disease progression.
Filiaciones:
Calva, CD:
Hosp Univ & Politecn La Fe, Pathol Dept, Valencia 46026, Spain
Angulo, M:
Hosp Univ & Politecn La Fe, Pathol Dept, Valencia 46026, Spain
González-Rojo, P:
Hosp Univ & Politecn La Fe, Pathol Dept, Valencia 46026, Spain
Peiró, A:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain
Machado, P:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain
Cebrián, JL:
Hosp Clin San Carlos, Madrid 28040, Spain
García-Maroto, R:
Hosp Clin San Carlos, Madrid 28040, Spain
Valcárcel, A:
Hosp Clin Univ Virgen Arrixaca, Murcia 30120, Spain
Puertas, P:
Hosp Clin Univ Virgen Arrixaca, Murcia 30120, Spain
Valero-Cifuentes, G:
Hosp Clin Univ Virgen Arrixaca, Murcia 30120, Spain
Pablos, O:
Hosp Univ Bellvitge, Barcelona 08907, Spain
Maireles, M:
Hosp Univ Bellvitge, Barcelona 08907, Spain
Fontalva, ML:
Hosp Univ Bellvitge, Barcelona 08907, Spain
Chaves, I:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife 38010, Spain
Orce, A:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife 38010, Spain
Coll-Mesa, L:
Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife 38010, Spain
Pérez, I:
Hosp Univ Ramon & Cajal, Madrid 28034, Spain
González, F:
Hosp Univ Ramon & Cajal, Madrid 28034, Spain
Sanz, MD:
Hosp Univ Ramon & Cajal, Madrid 28034, Spain
Gracia, I:
Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona 08025, Spain
Green Submitted, gold
|